免疫疗法在 III 期非小细胞肺癌中的演进角色。
The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer.
机构信息
Division of Medical Oncology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Medical Oncology/Hematology, William Osler Health System, Brampton, ON L6R 3J7, Canada.
出版信息
Curr Oncol. 2021 Dec 16;28(6):5408-5421. doi: 10.3390/curroncol28060451.
Abstract
The management of Stage III non-small cell lung cancer (NSCLC) is complex and requires multidisciplinary input. Since the publication of the PACIFIC trial (consolidative durvalumab post concurrent chemotherapy and radiation in Stage III disease) which showed improved survival for patients in the immunotherapy arm, there has been much interest in the use of immunotherapy in the Stage III setting. In this review, we explore the biologic and clinical rationale for the use of immunotherapy in Stage III NSCLC, present previously published and upcoming data in the neoadjuvant, adjuvant, and concurrent realms of Stage III management, and discuss unanswered questions and challenges moving forward.
摘要
III 期非小细胞肺癌（NSCLC）的治疗非常复杂，需要多学科的共同参与。PACIFIC 试验（III 期患者接受同步放化疗后巩固性 durvalumab 治疗）发表后，免疫治疗组患者的生存得到了改善，这引起了人们对免疫治疗在 III 期治疗中的应用的极大兴趣。在这篇综述中，我们探讨了免疫治疗在 III 期 NSCLC 中的生物学和临床依据，介绍了在 III 期治疗的新辅助、辅助和同步治疗领域中已发表和即将发表的数据，并讨论了未来仍需解决的问题和挑战。
相似文献
1
The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer.
Curr Oncol. 2021 Dec 16;28(6):5408-5421. doi: 10.3390/curroncol28060451.
2
Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial.
Clin Lung Cancer. 2022 May;23(3):e247-e251. doi: 10.1016/j.cllc.2021.09.010. Epub 2021 Oct 10.
3
Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era.
Crit Rev Oncol Hematol. 2022 Jun;174:103684. doi: 10.1016/j.critrevonc.2022.103684. Epub 2022 Apr 21.
4
Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors.
Immunotherapy. 2022 Aug;14(12):927-944. doi: 10.2217/imt-2021-0341. Epub 2022 Jul 13.
5
Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience.
Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619885530. doi: 10.1177/1753466619885530.
6
Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches.
Ann Oncol. 2022 Sep;33(9):893-908. doi: 10.1016/j.annonc.2022.06.013. Epub 2022 Jun 28.
7
Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
Lung Cancer. 2019 Aug;134:259-267. doi: 10.1016/j.lungcan.2019.05.027. Epub 2019 May 29.
8
Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer.
Radiother Oncol. 2020 Mar;144:101-104. doi: 10.1016/j.radonc.2019.11.015. Epub 2019 Nov 28.
9
Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.
Curr Oncol. 2023 Mar 27;30(4):3684-3696. doi: 10.3390/curroncol30040280.
10
Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease.
Curr Oncol. 2023 Oct 29;30(11):9514-9529. doi: 10.3390/curroncol30110689.
引用本文的文献
1
Adjuvant Immunotherapy for Resectable Non-Small Cell Lung Cancer: Current Advances and Future Perspectives.
Cancers (Basel). 2025 Jun 23;17(13):2099. doi: 10.3390/cancers17132099.
2
Immunotherapy in Thoracic Malignancies: New Treatment and New Hope.
Curr Oncol. 2022 Feb 2;29(2):834-836. doi: 10.3390/curroncol29020070.
本文引用的文献
1
Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO).
J Immunother Cancer. 2022 Oct;10(10). doi: 10.1136/jitc-2022-005636.
2
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Lancet. 2021 Oct 9;398(10308):1344-1357. doi: 10.1016/S0140-6736(21)02098-5. Epub 2021 Sep 20.
3
Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
ESMO Open. 2021 Oct;6(5):100244. doi: 10.1016/j.esmoop.2021.100244. Epub 2021 Aug 31.
4
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer.
Nat Commun. 2021 Aug 19;12(1):5045. doi: 10.1038/s41467-021-25188-0.
5
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
J Clin Oncol. 2021 Sep 10;39(26):2872-2880. doi: 10.1200/JCO.21.00276. Epub 2021 Jul 12.
6
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.
Lancet Oncol. 2021 Jun;22(6):824-835. doi: 10.1016/S1470-2045(21)00149-2. Epub 2021 May 18.
7
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
Nat Med. 2021 Mar;27(3):504-514. doi: 10.1038/s41591-020-01224-2. Epub 2021 Feb 18.
8
A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study.
Oncologist. 2021 Jun;26(6):523-532. doi: 10.1002/onco.13725. Epub 2021 Mar 11.
9
Immune Checkpoint Inhibition With Chemoradiotherapy in Stage III Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis of Safety Results.
Clin Lung Cancer. 2021 Mar;22(2):74-82. doi: 10.1016/j.cllc.2020.10.023. Epub 2020 Nov 12.
10
Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer: Implications for Oncogene-Driven Lung Cancer.
Cancer J. 2020 Nov/Dec;26(6):517-524. doi: 10.1097/PPO.0000000000000491.
Zotero 插件